Related by context. Frequent words. (Click for all words.) 87 Initiates Phase 83 Completes Enrollment 82 Presents Positive 81 Announces Initiation 79 Pivotal Phase 78 Drug Candidate 78 Pivotal Phase III 76 Clinical Trial Results 76 FDA Clears 75 Patient Enrollment 75 Receives FDA Clearance 75 Announces Positive 75 Phase III Clinical Trial 75 Receives Positive 74 Announces Successful Completion 74 Reports Positive 74 Completes Initial 73 Preclinical Data 73 FDA Accepts 73 Announces Publication 73 Announces Issuance 72 Metastatic Melanoma 72 Updates Status 72 Announces Presentation 71 Successfully Completes 71 MKC# 71 Pivotal Trial 71 Achieves Milestone 71 Closes Financing 71 Inc Therapeutic Competitors 71 Phase III Trial 70 IIROC Halt 70 Chronic Hepatitis C 70 Monoclonal Antibody 70 Completes Successful 70 Announces Commencement 70 Announces Non Brokered 69 Acquires Exclusive 69 Commences Trading 69 Announces Termination 69 Secures Additional 69 Grants Options 69 Small Molecule 69 Announce Completion 69 Receives Regulatory 69 Study Demonstrates 68 Shows Promise 68 FDA Approves 68 Successful Completion 68 Announces Signing 68 Announces Completion 68 Patent Covering 68 Significantly Reduces 68 Begins Drilling 68 Announces Successful 68 Receives Patent 68 Patent Issued 68 Closes Private Placement 68 Provides Updates 68 Updates Shareholders 68 Q3 Loss Widens 68 Reduces Risk 68 Drilling Commences 68 Q1 Loss Narrows 67 Completes Private Placement 67 Q2 Loss Narrows 67 Near Surface 67 Announces Shareholder Approval 67 Provides Operational Update 67 Commence Trading 67 Commences Drilling 67 Closes Acquisition 67 Drilling Intersects 67 liposomal formulation 67 Announces Filing 67 Generic Version 67 Q3 Loss Narrows 67 Provides Update 67 BY DOUGLAS HANKS 67 Announces Private Placement 67 Adopts Shareholder Rights 67 Tesetaxel 67 Mln Common 67 Q2 Loss Widens 67 Awarded Patent 66 Nephrol 66 Inhibits 66 Q4 Loss Widens 66 Finalizes Acquisition 66 Regains Compliance With 66 Releases Third Quarter 66 Closes Sale 66 Marcus Gronholm BP 66 J Am Coll 66 Benign Prostatic Hyperplasia 66 Announces Normal Course 66 Q4 Loss Narrows 66 Skymark Research Initiates Independent 65 RNAi Therapeutics 65 Well Tolerated 65 Patients Treated